---
title: "PPL: Q2 adjusted EBITDA up 5% year-over-year, with new assets and major projects fueling growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294538495.md"
description: "Q2 2026 adjusted EBITDA rose 5% year-over-year to CAD 1.064 billion, with strong operational performance and new assets driving growth. Guidance for 2026 is reaffirmed, and major projects like Greenlight and Cedar LNG are advancing, supporting a robust long-term outlook.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-31T16:27:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294538495.md)
  - [en](https://longbridge.com/en/news/294538495.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294538495.md)
generator: "portal-rs"
---

# PPL: Q2 adjusted EBITDA up 5% year-over-year, with new assets and major projects fueling growth

Q2 2026 adjusted EBITDA rose 5% year-over-year to CAD 1.064 billion, with strong operational performance and new assets driving growth. Guidance for 2026 is reaffirmed, and major projects like Greenlight and Cedar LNG are advancing, supporting a robust long-term outlook.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [PBA.US](https://longbridge.com/en/quote/PBA.US.md)
- [PPL.US](https://longbridge.com/en/quote/PPL.US.md)
- [PPLC.US](https://longbridge.com/en/quote/PPLC.US.md)

## Related News & Research

- [Why Semtech (SMTC) Is Up 5.7% After Strong Q2 Results And AI-Focused Guidance – And What's Next](https://longbridge.com/en/news/297384085.md)
- [HOC: Record half-year results with strong cash flow, higher costs, and major project milestones achieved](https://longbridge.com/en/news/297067538.md)
- [AI Monetization: Goldman On 'Size Of The Pie' Versus 'Share Of The Pie' Worries](https://longbridge.com/en/news/297359410.md)
- [ALMS: Envudeucitinib showed strong efficacy in IFNGS-high SLE patients and was well tolerated](https://longbridge.com/en/news/297666957.md)
- [Key facts: Salesforce, Inc. Enhances Anthropic Tie; CRM Near $265](https://longbridge.com/en/news/297393365.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**